EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dermira's Enterprise Value is $1,025.53 Mil.
Dermira's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2019 was $-245.31 Mil. Therefore, Dermira's EV-to-FCF for today is -4.18.
The historical rank and industry rank for Dermira's EV-to-FCF or its related term are showing as below:
DERM's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 4.47 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-30), Dermira's stock price is $18.75.
Dermira's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.580. Therefore, Dermira's PE Ratio for today is At Loss.
Dermira EV-to-FCF Historical Data
The historical data trend for Dermira's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dermira's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermira's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dermira's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Dermira's EV-to-FCF falls into.
Dermira's current Enterprise Value is $1,025.53 Mil.
Dermira's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-245.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermira (NAS:DERM) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Dermira's share price for today is $18.75.
Dermira's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Dermira EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Dermira's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DERM has been successfully added to your 